B
Bruna Bronhara
Publications - 2
Citations - 341
Bruna Bronhara is an academic researcher. The author has contributed to research in topics: Randomized controlled trial & Rivaroxaban. The author has an hindex of 2, co-authored 2 publications receiving 71 citations.
Papers
More filters
Journal ArticleDOI
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Renato D. Lopes,Pedro Gabriel Melo de Barros e Silva,Remo H.M. Furtado,Ariane Vieira Scarlatelli Macedo,Bruna Bronhara,Lucas P. Damiani,Lilian Mazza Barbosa,Júlia de Aveiro Morata,Eduardo Ramacciotti,Priscilla de Aquino Martins,Aryadne Lyrio de Oliveira,Vinicius Santana Nunes,Luiz Eduardo Fonteles Ritt,Ana Thereza Rocha,Lucas Tramujas,Sueli V Santos,Dario Rafael Abregu Diaz,Lorena Souza Viana,Livia Maria Garcia Melro,Mariana Silveira de Alcântara Chaud,Estêvão Lanna Figueiredo,Fernando Carvalho Neuenschwander,Marianna Deway Andrade Dracoulakis,Rodolfo Godinho Souza Dourado Lima,Vicente C.S. Dantas,Anne Cristine Silva Fernandes,Otavio Gebara,Mauro E. Hernandes,Diego Aparecido Rios Queiroz,Viviane C Veiga,Manoel Fernandes Canesin,Leonardo Meira de Faria,Gilson Soares Feitosa-Filho,Marcelo Basso Gazzana,Idelzuíta Leandro Liporace,Aline de Oliveira Twardowsky,Lilia Nigro Maia,Flávia Ribeiro Machado,Alexandre de Matos Soeiro,Germano Emílio Conceição-Souza,Luciana Armaganijan,Patrícia O. Guimarães,Regis Goulart Rosa,Luciano Cesar Pontes Azevedo,John H. Alexander,Alvaro Avezum,Alexandre Biasi Cavalcanti,Otavio Berwanger +47 more
TL;DR: In this paper, the authors compared the efficacy and safety of therapeutic versus prophylactic anticoagulation in patients hospitalised with COVID-19 in 31 sites in Brazil, and found that in the case of stable patients, in-hospital oral rivaroxaban (20 mg or 15 mg daily) or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0·3-0·7 IU/mL anti-Xa concentration) for clinically unstable patients, followed
Journal ArticleDOI
Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
Renato D. Lopes,Pedro Gabriel Melo de Barros e Silva,Remo H.M. Furtado,Ariane Vieira Scarlatelli Macedo,Eduardo Ramacciotti,Lucas Petri Damini,Bruna Bronhara,Alexandre Biasi Cavalcanti,Regis Goulart Rosa,Luciano Cesar Pontes Azevedo,Viviane C Veiga,Flávia Ribeiro Machado,Luiz Eduardo Fonteles Ritt,Priscilla de Aquino Martins,John H. Alexander,Alvaro Avezum,Otavio Berwanger,Coalition Covid Brazil Iv Investigators +17 more
TL;DR: Action as discussed by the authors is an academic-led, pragmatic, multicenter, open-label, randomized, phase IV clinical trial that aims to enroll around 600 patients at 40 sites participating in the Coalition COVID-19 Brazil initiative.